Ubs Asset Management Americas Inc Verve Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 133,566 shares of VERV stock, worth $641,116. This represents 0.0% of its overall portfolio holdings.
Number of Shares
133,566
Previous 119,818
11.47%
Holding current value
$641,116
Previous $675,000
9.63%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.5MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$59.3 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$33.1 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$31.8 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$19.2 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$19 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $288M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...